HDAC9 and non-small cell lung carcinoma: Previous studies have demonstrated that HDAC inhibitors can suppress survivin [38, 39], which has been mechanistically linked to regulation of miR-203 in NSCLC tumor models [40], as well as to activation of AMP-activated protein kinase (AMPK) or the MAPK pathway (P38) in colon cancer models [41].